I en undersøgelse af patienter med type 2- diabetes og kronisk nyreinsufficiens (kreatinin- clearance < 50 ml/ min) blev sikkerheden og tolerancen for reducerede doser af sitagliptin undersøgt og var generelt den samme som for placebo.
In a study in patients with type 2 diabetes and chronic renal insufficiency (creatinine clearance < 50 ml/ min), the safety and tolerability of reduced doses of sitagliptin were investigated and generally similar to placebo.